A large-scale clinical study from The National Cancer Institute (NCI) demonstrated that x-ray low dose CT screening sharply reduced lung cancer deaths by detecting cancers at relatively early stages. Patients screened with x-ray low dose CT were 20% less likely to die from lung cancer compared with standard chest x-ray. Annual screening by x-ray low dose CT has the potential to detect lung cancers in their earliest stage, when survival is most promising. The study, while positive, also showed that low-dose CT scans tend to have a high false positive rate – an area for improvement where VisionGate is focused.

A major milestone for lung cancer screening, the Centers for Medicare and Medicaid (CMS) approved reimbursing low-dose CT scans in a high-risk group of patients (ages 55-77 who have smoked one pack of cigarettes a day for 30 years) in February 2015, issuing instructions for submitting claims in October 2015 to start accepting claims in January 2016.

About LuCED® Lung Test

The LuCED lung test does not use radiation. Rather, it uses a sputum sample that can be collected through spontaneous coughs over a three-day period using a take-home test kit. Samples collected using our LuCED test kits are shipped to the VisionGate Biosignatures Laboratory (VBL) and then samples are processed on our proprietary Cell-CT technology. The first automated 3D cell imaging platform, this revolutionary technology computes sub-micron resolution biosignatures from intact cells. Cell classifiers then automatically identify abnormal cells in sputum. Please view the Cost-Effectiveness study conducted by the University of Arizona.

VisionGate currently has collaborations or pending IRBs with:

NYU Langone Cancer Center Kaiser Permanente
Fred Hutchinson Cancer Research Center Swedish Cancer Institute
Memorial Sloan Kettering Toronto General Hospital
Cancer Treatment Centers of America Dignity Health
Oregon Health & Science University University of Navarra (Spain)
Aristotle University (Greece)

To discuss opportunities, please contact VisionGate at 602.354.8862 or send an email to

Notify Me When It Arrives

    Complete the fields below to be notified when our LuCED® Lung Cancer Test becomes available.

    Your Name (required)

    Your Email (required)

    Your State (required)

    Contact Us

    If you are interested in learning more about the VisionGate® Cell-CT™ technology and would like to speak with someone, please complete this short inquiry form and a VisionGate representative will contact you as soon as possible.

    Copyright 2021 - VisionGate, Inc.